The European Medicines Agency recently finalized a review on cardiovascular safety and nonsteroidal anti-inflammatory drugs (NSAIDs). This review included newly published articles (meta-analysis of clinical trials and observational studies, and the results of the Safety of Nonsteroidal Anti-inflammatory Drugs (SOS) project) on three of the most commonly used NSAIDs (diclofenac, ibuprofen, and naproxen). The review concluded that compared to other NSAIDs, diclofenac had a small increase in the risk cardiovascular events, similar to that of COX-2 inhibitors. What important counseling points would you provide to your patients who are taking NSAIDs?
For more information, please read the article in the EMA.